Nuklearmedizin-nuclear Medicine最新文献

英文中文

DGN-Summer School 2023 2023年夏季学校

4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-03-30 DOI: 10.1055/a-2040-9453

Wir freuen uns, nach einer 3-jährigen „Corona-Pause“ in diesem Jahr vom 24.-26. August 2023 die DGN-Summer School wieder an der Charité in Berlin zum Thema „Translational Research in Molecular Imaging and Radionuclide Therapy“ durchzuführen. Die wissenschaftliche Leitung liegt erneut bei Prof. Dr. Winfried Brenner, Berlin (D), Prof. Dr. Martin Gotthardt, Nijmegen (NL), und Prof. Dr. Felix M. Mottaghy, Aachen und Maastricht (NL).

今晚的"科罗那午休"结束了三年，一共24、26年2023年8月DGN-Summer elementary School再一次在Charité柏林主题”的文化研究在Molecular Imaging and Radionuclide治愈的“执行.科学委员会由柏林的温弗里德·班纳博士教授领导

引用次数: 0

Intraindividual Comparison of Physiologic [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: a retrospective, monocentric analysis 前列腺癌患者神经节生理性[68Ga]Ga-PSMA-11和[18F]PSMA-1007摄取的个体内比较:回顾性单中心分析

4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-03-30 DOI: 10.1055/s-0043-1766379

E. Novruzov, D. Schmitt, K. Mattes-György, M. Beu, J. M. Henke, C. Antke, J. Cardinale, G. Niegisch, L. Schimmöller, F. L. Giesel, E. Mamlins

Ziel/Aim Several studies indicate a relatively high rate of detection of benign findings, in particular ganglia, in PSMA PET imaging. To date, no studies have directly compared [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 ganglionic uptake intraindividually and analyzed the different detection rates and underlying molecular and physical mechanisms. With this monocentric retrospective study, we sought to evaluate the intraindividual physiological ganglion uptake of different PSMA ligands.

几项研究表明，在PSMA PET成像中，良性发现的检出率相对较高，尤其是神经节。到目前为止，还没有研究直接比较[68Ga]Ga-PSMA-11和[18F]PSMA-1007在个体内的神经节摄取，并分析不同的检出率及其潜在的分子和物理机制。通过这项单中心回顾性研究，我们试图评估个体内不同PSMA配体的生理神经节摄取。

引用次数: 0

Prognostic value of tumor volume assessment on PSMA PET after [Lu-177]PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0 用PSMA PET/CT共识声明和RECIP 1.0评价[Lu-177]PSMA放射配位治疗后肿瘤体积评估的预后价值

4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-03-30 DOI: 10.1055/s-0043-1766156

F. Kind, A. C. Eder, C. A. Jilg, P. E. Hartrampf, P. T. Meyer, J. Ruf, K. Michalski

Ziel/Aim Quantitative assessments of positron emission tomography/computer tomography targeting the prostate specific membrane antigen (PSMA PET/CT) are promising for the evaluation of response to [Lu-177]PSMA radioligand therapy (PSMA RLT). Both the updated PSMA PET/CT consensus statement (CS) [1] as well as the recently introduced Response Evaluation Criteria In PSMA-PET/CT (RECIP 1.0) [2], strongly emphasize the change in whole-body tumor volume as a major response criterion. PSMATV50 [3], based on a 50% threshold of the lesional maximum standardized uptake value, appears to be a promising parameter for whole-body tumor volume determination. In the present study PSMATV50 was used for both CS and RECIP 1.0 in order to assess their predictive value for overall survival (OS).

针对前列腺特异性膜抗原的正电子发射断层扫描/计算机断层扫描(PSMA PET/CT)的定量评估有望用于评估[Lu-177]PSMA放射配体治疗(PSMA RLT)的疗效。更新的PSMA PET/CT共识声明(CS)[1]和最近推出的PSMA-PET/CT反应评价标准(RECIP 1.0)[2]都强烈强调全身肿瘤体积的变化是主要的反应标准。基于病变最大标准化摄取值的50%阈值，PSMATV50[3]似乎是测定全身肿瘤体积的一个有希望的参数。在本研究中，PSMATV50用于CS和RECIP 1.0，以评估其对总生存期(OS)的预测价值。

引用次数: 1

Peptide Receptor Radionuclide Therapy in Patients with Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety and Survival Predictors 晚期进行性甲状腺髓样癌患者的肽受体放射性核素治疗:疗效、安全性和生存预测因子

4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-03-30 DOI: 10.1055/s-0043-1766219

Q. X. Liu, H. R. Kulkarni, T. Z. Zhao, C. Schuchardt, X. Chen, Z. H. Zhu, J. Zhang, R. P. Baum

Ziel/Aim Metastatic medullary thyroid carcinoma (MTC) is often has a rapid disease progression and poor prognosis with few therapeutic options available. Peptide Receptor Radionuclide Therapy (PRRT) has demonstrated success in the management of gastroenteropancreatic neuroendocrine tumors and has also been used to treat MTC. The objective of this study was to assess the safety and efficacy of PRRT in patients with advanced, progressive MTC, to determine survival and potential predictors of survival.

转移性甲状腺髓样癌(MTC)通常病情进展迅速，预后差，治疗选择很少。肽受体放射性核素疗法(PRRT)在胃肠胰神经内分泌肿瘤的治疗中已被证明是成功的，也已被用于治疗MTC。本研究的目的是评估PRRT在晚期进展性MTC患者中的安全性和有效性，以确定生存和潜在的生存预测因素。

引用次数: 0

Voxel-based dosimetry predicts hepatotoxicity in hepatocellular carcinoma patients undergoing radioembolization with 90Y glass microspheres 基于体素的剂量法预测接受90Y玻璃微球放射栓塞的肝癌患者的肝毒性

4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-03-30 DOI: 10.1055/s-0043-1766312

M. Watanabe, H. Grafe, J. Theysohn, B. Schaarschmidt, J. Ludwig, L. Jochheim, M. Jeschke, H. Schmidt, W. P. Fendler, A. Moraitis, K. Herrmann, K. L. Pomykala, M. Weber

Ziel/Aim Personalized dosimetry holds promise to improve radioembolization treatment outcomes in hepatocellular carcinoma (HCC) patients. To this end, tolerance doses for healthy liver tissue (HLT) are assessed by calculating the mean whole-liver normal tissue dose (WLNT), which neglects non-uniform dose distribution. Thus, we analyzed whether voxel-based dosimetry could be more accurate in predicting hepatotoxicity in HCC patients undergoing radioembolization.

个体化剂量测定有望改善肝细胞癌(HCC)患者的放射栓塞治疗效果。为此，通过计算全肝正常组织平均剂量(WLNT)来评估健康肝组织(HLT)的耐受剂量，忽略了剂量分布的不均匀性。因此，我们分析了基于体素的剂量学是否可以更准确地预测接受放射栓塞治疗的HCC患者的肝毒性。

引用次数: 0

Personalia 个人

4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-03-30 DOI: 10.1055/a-2040-9488

PD Dr. Christoph Rischpler ([Abb. 1]) ist seit Januar 2023 neuer Ärztlicher Direktor der Klinik für Nuklearmedizin im Klinikum Stuttgart. Er war zuletzt kommissarischer Leiter der Nuklearmedizin im Evangelischen Bethesda-Krankenhaus zu Duisburg sowie W2-Professor für nuklearkardiologische Bildgebung am Universitätsklinikum Essen. Sein Medizinstudium hat der Facharzt für Nuklearmedizin unter anderem in München, San Francisco und Sydney absolviert. Am Klinikum Stuttgart möchte Christoph Rischpler die nuklearkardiologische Bildgebung und neue Therapien wie die PSMA-Radioligandentherapie und die Peptid-Radiorezeptortherapie stärken. Dazu strebt er die Zertifizierung der Klinik als nuklearkardiologisches Zentrum an.

从2023年1月起，图一已担任斯图加特医疗中心新的医疗主任。他任职于新教的杜伊斯堡贝塞斯达医院，并是w2核心脏病扫描教授。他的医学学位来自慕尼黑、旧金山和悉尼。斯图加特诊所的Christoph Rischpler希望加强核心外科成像和新的疗法，如psma放射治疗和petid放射治疗。他想开这所医院

引用次数: 0

Bestimmung der Aktivitätskonzentration von Nuklidgemischen von I-131 und Lu-177m/Lu-177 im Abwasser einer nuklearmedizinischen Therapiestation. Methode 1 检测一个核治疗中心污水中方法1

4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-03-30 DOI: 10.1055/s-0043-1766289

D. Kupitz, E. Einspänner, H. Wissel, A. Hohn, M. C. Kreissl, O. S. Grosser

Ziel/Aim Für die Freigabe radioaktiver Stoffe lt. StrlSchV ist die Quantifizierung der vorliegenden Nuklide erforderlich. Hierfür wurden zwei Methoden für die Analyse von Nuklidgemischen (I-131 und Lu-177m/Lu-177) untersucht. In der hier vorgestellten Methode werden die Energiespektren einer Probe zu zwei Zeitpunkten gemessen und die spezifischen Aktivitätskonzentrationen (AKs) der vorhandenen Nuklide ermittelt. Ein typisches Nutzungsszenario ist die Freigabe von Abwässern aus einer Abwasserschutzanlage.

目标/Aim发放放射性物质的对象t. StrlSchV是需要量化介绍介绍的nu变化。本研究研究了两种突变分析方法(i本篇提出的方法是，在一次实验中，在两个时期测量能量谱，并计算指定的活动水平(ak)在现有的活动链中。典型的使用评价是将污水保护设施中的排泄物释放

引用次数: 0

Radioiodine ablation of thyroid remnants in patients with Graves’ orbitopathy 放射性碘消融治疗Graves眼病患者甲状腺残余物

4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-03-30 DOI: 10.1055/s-0043-1766224

M. Weber, J. Koenen, N. Bechrakis, M. Stöhr, K. Herrmann, W. P. Fendler, A. Eckstein, M. Oeverhaus

Ziel/Aim To assess response following ablation of thyroid remnants (ATR) with radioactive iodine therapy (RAIT) in patients with unstable Graves’ orbitopathy (GO) after (subtotal) thyroidectomy.

目的评价(次全)甲状腺切除术后不稳定Graves眼病(GO)患者甲状腺残余(ATR)消融与放射性碘治疗(RAIT)的疗效。

引用次数: 0

Adverse events unlikely after fine-needle aspiration biopsies of thyroid nodules in patients on low-dose aspirin: a prospective controlled systematic single center analysis. 低剂量阿司匹林患者甲状腺结节细针穿刺活检后不可能发生不良事件:一项前瞻性对照系统单中心分析。

IF 1.5 4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-02-01 DOI: 10.1055/a-1972-9372

Michael Cordes, Theresa Ida Götz, Torsten Kuwert, Christian Schmidkonz

Aim: Our aim was to test the assertion that in terms of rate or severity level, adverse events (AEs) after fine-needle aspiration biopsies (FNABs) of thyroid nodules are unfazed by daily low-dose (100 mg) aspirin (acetylsalicylic acid, ASA) intake.

Methods: We selected 268 patients for study, grouped as ASA-treated (P_ASA, n=78) or control (P_Ctrl, n=190) subjects. Controls received no antithrombotic medication. AE rates and severities were then analyzed based on patient- and nodule-related factors. We also compared group rates of non-diagnostic cytology results.

Results: AEs arising after FNABs (P_ASA, 5%; P_Ctrl, 8%) did not differ significantly by group in rate (p=0.4873) or severity level (p=0.3399). All were classifiable as minor incidents, none warranting any intervention.

Conclusions: The data from the present study suggest, AEs after FNABs of thyroid nodules seldom occur and qualify as minor incidents. Such procedures may be safely conducted in patients taking daily low-dose ASA. There is no evidence to support preemptive therapeutic withdrawal.

目的:我们的目的是验证在甲状腺结节细针穿刺活检(fnab)后不良事件(ae)的发生率或严重程度方面，每日低剂量(100mg)阿司匹林(乙酰水杨酸，ASA)摄入不受影响的断言。方法:我们选择268例患者进行研究，分为asa治疗组(PASA, n=78)和对照组(PCtrl, n=190)。对照组未接受抗血栓药物治疗。然后根据患者和结节相关因素分析AE发生率和严重程度。我们还比较了各组非诊断性细胞学结果的发生率。结果:fnab后产生ae (PASA, 5%;PCtrl, 8%)在发生率(p=0.4873)或严重程度(p=0.3399)上各组无显著差异。所有这些都被归类为小事件，没有必要进行任何干预。结论:本研究资料提示，甲状腺结节fnab后的ae很少发生，属于轻微事件。对于每日服用低剂量ASA的患者，这样的操作是安全的。没有证据支持先发制人的治疗性停药。

{"title":"Adverse events unlikely after fine-needle aspiration biopsies of thyroid nodules in patients on low-dose aspirin: a prospective controlled systematic single center analysis.","authors":"Michael Cordes, Theresa Ida Götz, Torsten Kuwert, Christian Schmidkonz","doi":"10.1055/a-1972-9372","DOIUrl":"https://doi.org/10.1055/a-1972-9372","url":null,"abstract":"Aim: Our aim was to test the assertion that in terms of rate or severity level, adverse events (AEs) after fine-needle aspiration biopsies (FNABs) of thyroid nodules are unfazed by daily low-dose (100 mg) aspirin (acetylsalicylic acid, ASA) intake.Methods: We selected 268 patients for study, grouped as ASA-treated (PASA, n=78) or control (PCtrl, n=190) subjects. Controls received no antithrombotic medication. AE rates and severities were then analyzed based on patient- and nodule-related factors. We also compared group rates of non-diagnostic cytology results.Results: AEs arising after FNABs (PASA, 5%; PCtrl, 8%) did not differ significantly by group in rate (p=0.4873) or severity level (p=0.3399). All were classifiable as minor incidents, none warranting any intervention.Conclusions: The data from the present study suggest, AEs after FNABs of thyroid nodules seldom occur and qualify as minor incidents. Such procedures may be safely conducted in patients taking daily low-dose ASA. There is no evidence to support preemptive therapeutic withdrawal.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"34-37"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9220502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT]. 前列腺癌psma配体PET/CT成像程序指南

IF 1.2 4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuklearmedizin-nuclear Medicine

Pub Date : 2023-02-01 Epub Date: 2023-02-06 DOI: 10.1055/a-1984-8167

Ali Afshar-Oromieh, Matthias Eiber, Wolfgang Fendler, Matthias Schmidt, Kambiz Rahbar, Hojjat Ahmadzadehfar, Lale Umutlu, Boris Hadaschik, Oliver W Hakenberg, Paolo Fornara, Jens Kurth, O Neels, Hans-Jürgen Wester, Markus Schwaiger, Klaus Kopka, Uwe Haberkorn, Ken Herrmann, Bernd J Krause

PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. ⁶⁸Ga-PSMA-11, ⁶⁸Ga-PSMA-I&T, ⁶⁸Ga-PSMA-617, ¹⁸F-DCFBC, ¹⁸F-DCFPyL, ¹⁸F-PSMA-1007, ¹⁸F-rhPSMA-7 and ¹⁸F-JK-PSMA-7). However, an official approval is available only for ⁶⁸Ga-PSMA-11 (approved by the US FDA in 2020) and ¹⁸F-DCFPyL (approved by the US FDA in 2021).Recommendations for acquisition times vary from 1-2 h p. i. It has been shown that for the majority of tumour lesions, the contrast in PSMA-PET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder.PSMA-ligands are physiologically taken up in multiple normal organs. For some ¹⁸F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e. g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.

自2011年临床应用以来，PSMA-PET/CT用于前列腺癌（PC）成像已在全球范围内推广。大部份的经验是收集于复发性PC的psma - pet影像。高危PC的初级分期数据是非常有希望的。同时，大量的psma配体可用于临床应用(例如。68Ga-PSMA-11, 68Ga-PSMA-I&T, 68Ga-PSMA-617, 18F-DCFBC, 18F-DCFPyL, 18F-PSMA-1007, 18F-rhPSMA-7和18F-JK-PSMA-7)。然而，官方批准仅适用于68Ga-PSMA-11（2020年由美国FDA批准）和18F-DCFPyL（2021年由美国FDA批准）。采集时间的建议从1-2小时不等。研究表明，对于大多数肿瘤病变，PSMA-PET/CT的对比随着时间的推移而增加。因此，额外的晚期影像学检查有助于澄清不明确的发现。PSMA-PET/CT应该在开始雄激素剥夺治疗（ADT）之前进行，因为（长期）ADT降低了PC病变的可见性。注射psma配体后，建议对主要通过肾脏排泄的psma配体进行水化和强制利尿，以增加膀胱附近肿瘤病变的可见性。psma配体在生理上被多种正常器官吸收。对于一些18f标记的psma配体，有报道称存在非特异性局灶性骨摄取。当使用这些示踪剂时，没有ct相关的局灶性骨摄取应该非常谨慎地解释。除前列腺癌外，几乎所有实体肿瘤都在其新生血管中表达PSMA，从而吸收PSMA配体，尽管与PC相比，表达PSMA的程度通常较低。还有多种良性病变和炎症过程(如：淋巴结)占用psma配体，通常也比PC低。

{"title":"[Procedure Guideline for Prostate Cancer Imaging with PSMA-ligand PET/CT].","authors":"Ali Afshar-Oromieh, Matthias Eiber, Wolfgang Fendler, Matthias Schmidt, Kambiz Rahbar, Hojjat Ahmadzadehfar, Lale Umutlu, Boris Hadaschik, Oliver W Hakenberg, Paolo Fornara, Jens Kurth, O Neels, Hans-Jürgen Wester, Markus Schwaiger, Klaus Kopka, Uwe Haberkorn, Ken Herrmann, Bernd J Krause","doi":"10.1055/a-1984-8167","DOIUrl":"10.1055/a-1984-8167","url":null,"abstract":"PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. 68Ga-PSMA-11, 68Ga-PSMA-I&T, 68Ga-PSMA-617, 18F-DCFBC, 18F-DCFPyL, 18F-PSMA-1007, 18F-rhPSMA-7 and 18F-JK-PSMA-7). However, an official approval is available only for 68Ga-PSMA-11 (approved by the US FDA in 2020) and 18F-DCFPyL (approved by the US FDA in 2021).Recommendations for acquisition times vary from 1-2 h p. i. It has been shown that for the majority of tumour lesions, the contrast in PSMA-PET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder.PSMA-ligands are physiologically taken up in multiple normal organs. For some 18F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e. g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"5-19"},"PeriodicalIF":1.2,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10667811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Nuklearmedizin-nuclear Medicine

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀